Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Status:
Recruiting
Trial end date:
2022-08-10
Target enrollment:
Participant gender:
Summary
This multicenter randomized, open-label study aimed to compare the efficacy and safety of
eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was
be conducted in adult ITP patients who had not responded to or had relapsed after previous
treatment of ITP, including first line therapy and /or splenectomy.
Phase:
Phase 4
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Collaborators:
Henan Cancer Hospital Nantong University The First Affiliated Hospital of Xiamen University The Second Affiliated Hospital of Kunming Medical University Tianjin Medical University Second Hospital